In 2015, Xiang and coworkers [56] reported an impaired cognition as well as the downregulation of Akt, CREB and BDNF in the hippocampi of streptozotocin-treated rats, results that may offer a new way to impede diabetes-induced encephalopathy and cognitive deficits in AD. Here, AKT1 is linked to Alzheimer disease.